



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Blood Cancers

## What to Expect and What is New

Raya Mawad, MD  
Swedish Cancer Institute  
Seattle, WA



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

© Original Artist

Reproduction rights obtainable from

[www.CartoonStock.com](http://www.CartoonStock.com)






**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>





**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# What is Blood Cancer?

Cancer of certain types of blood cells:

- Myeloid Cells

  - Myelodysplastic Syndrome (MDS)

  - Acute Myeloid Leukemia (AML)

  - Chronic Myeloid Leukemia (CML)

- Lymphoid Cells:

  - Lymphoma

  - Chronic Lymphoid Leukemia (CLL)

  - Acute Lymphoid Leukemia (ALL)

Plasma cells:

  - MGUS

  - Multiple Myeloma



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

## Organs of the Immune System




Figure 1.8 Janeway's Immunobiology, 8ed. (© Garland Science 2012)




**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Anatomy of a Lymph Node






**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>






**SWEDISH**

CANCER INSTITUTE


Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>



## Lymphomagenesis in Autoimmune Diseases



# Balancing Cell Production With Cell Death






**SWEDISH**  
CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Tumor Progression & Clonal Evolution



Courtesy of T. Miller, MD



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Lymphoma, Leukemia & Myeloma Symptoms

**Swelling of lymph nodes (Lymphoma or lymphoid leukemia)**

**-often, but not always painless**

**Fever**

**Drenching Night sweats**

**Unexplained weight loss (> 10% baseline in a few months)**

**Lack of energy**

**Low blood counts or abnormally high white blood count**

**Recurrent or Persistent infection (leukemia)**

**Bone Pain**

**Fractures or bone abnormalities on imaging**

# Risk Factors

**Immunodeficiency disorders**

**Autoimmune disorders**

**Organ transplantation (immunosuppressed)**

**Chemical or pesticide exposure (high level benzene, chemo)**

**Radiation exposure (atomic bomb survivors)**

**Bacteria or viruses (HIV, Hepatitis, EBV, HTLV-1, H. pylori)**



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Lymphoma Staging

**Stage I** - Cancer is found only in a single lymph node or in one organ or area outside the lymph node

**Stage II** - Cancer is found in two or more lymph nodes regions on one side of the diaphragm

**Stage III** - Cancer involves lymph nodes above and below the diaphragm

**Stage IV** - Cancer is found in several parts of one or more organs or tissues (in addition to the lymph nodes); or, it is in the liver, blood or bone marrow



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Lymphoma Prognosis & Characterization

**How fast is the lymphoma growing? Is it aggressive?**

**What Stage lymphoma?**

**Patient age & functional status**

**Genetics and surface protein expression of lymphoma cells**

# Leukemia Prognosis/Characterization

**Chronic vs Acute**

**Lymphoid or Myeloid**

**Percentage of leukemia cells (blasts) in bone marrow**

**What are the other blood counts**

**What are the genetic mutations in the leukemia cells**



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Myeloma

**Percentage of plasma cells in bone marrow**

**How high is the abnormal protein made by those plasma cells**

**Any end organ involvement (bone lesions, low blood counts, kidneys affected, high calcium)**

**Genetics of the plasma cells**





**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Diagnosis

## **Physical examination**

- > Enlarged lymph node or spleen

## **Biopsy**



- > Adequate tissue imperative
- > Excisional node biopsy (optimal)
- > Bone Marrow biopsy (leukemia, myeloma & often lymphoma)
- > Fine needle aspiration is often inadequate for lymphoma

## **Adequate immunophenotyping**

- > Immunohistochemistry to look at surface protein expression
- > Flow cytometry to detect cell surface markers

**Cytogenetics/FISH to detect genetic abnormalities when appropriate**

# Acute leukemia or Myeloma








**SWEDISH**

CANCER INSTITUTE


Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Follicular lymphoma





# Diffuse Large B Cell Lymphoma



The lymph node has solid sheets of large malignant looking lymphocytes. Relatively fast growing.



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Lymphoma Staging Evaluation

**History and complete physical examination**

**Laboratory evaluation**

> Standard blood studies

- Complete blood count, differential blood count, blood smear examination
- LDH and  $\beta$ 2-microglobulin
- Liver function tests
- Renal function tests
- Serum electrolyte, calcium and uric acid levels

**Bone marrow**

> Leukemia, myeloma & many lymphomas

**Radiologic studies**

> CT scans (abdomen, pelvis and thorax)/PET in selected histology's

# WHO Classification of B-Cell Neoplasms

## ***Precursor B-cell neoplasm***

- Precursor B-lymphoblastic leukemia/lymphoma (precursor B-cell acute lymphoblastic leukemia)

## ***Mature (peripheral) B-cell neoplasms***

- B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
- B-cell prolymphocytic leukemia
- Lymphoplasmacytic lymphoma
- Splenic marginal zone B-cell lymphoma (with or w/o villous lymphocytes)
- Hairy cell leukemia
- Plasma cell myeloma/plasmacytoma
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type
- Nodal marginal zone B-cell lymphoma (with or w/o monocytoid B cells)
- Follicular lymphoma
- Mantle cell lymphoma
- Diffuse large B-cell lymphoma
- Mediastinal large B-cell lymphoma
- Primary effusion lymphoma
- Burkitt's lymphoma/Burkitt's cell leukemia

# How Does One Decide Which Treatment to Recommend?

## **Classification**

- > Subtype

## **Growth rate (grade)**

- > Indolent vs. Aggressive

## **Stage of disease**

- > Local, distant, widespread

## **Prognostic Factors**

- > IPI, FLIPI, MIPI

## **Other factors**

# Treatment Options

## **Watchful waiting:**

- slow growing (indolent) lymphomas**
- low risk, early MDS (precursor to AML)**
- low risk MGUS (precursor to myeloma)**

**Chemotherapy: various DNA damaging agents (usually through IV)**

**Radiation therapy (lymphoma or myeloma)**

**Immunotherapy and targeted agents**

**Stem cell transplantation**



# Watchful Waiting

**Often for indolent low-grade NHLs**

**Low risk, early MDS (precursor to AML)**

**Low risk MGUS (precursor to myeloma)**

- > Regular physical exam and lab evaluation
- > No treatment until patient has:
  - Symptoms- fever, chills, night sweats, weight loss
  - Signs the disease is progressing
  - lower blood counts, worsening kidney function
- > Treatment of indolent lymphoma at diagnosis does not improve survival or decrease incidence of transformation to a more aggressive lymphoma

# Chemotherapy (Chemo)

**Various drugs that affect DNA replication & cell growth**

**Different administration, schedule & side effects**

**Often given in combination**

**Often given IV and requires central venous access**

**-PORT or PICC or Hickman**




**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Chemotherapy





**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Chemo Side Effects

## Non-drug specific

- > Fatigue, loss of appetite, low energy
- > Nausea, vomiting, diarrhea
- > Low blood counts
  - White cells: risk of infections
  - Platelets: risk of bruising/bleeding
  - Red cells: anemia
- > Hair loss, skin and nail changes

## Chemo agent-specific

- > Doxorubicin- heart toxicity (heart failure)
- > Vincristine- nerve ending toxicity (neuropathy)
- > Prednisone- high blood sugar, agitation, loss of sleep, stomach irritation, “shakiness”

# Radiation Therapy

**Used primarily in early stage lymphomas**

**Can be used for palliative (symptom) therapy**

## **Acute side effects**

> Nausea/vomiting, inflammation, fatigue, pain

## **Long term side effects**

> Risk of secondary cancers, risk of marrow failure, risk of heart disease and pulmonary fibrosis

**Usually combined with chemotherapy**



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# External Beam Radiation



# Stem Cell Transplantation

## -Autologous vs Allogeneic

- Autologous: used in relapsed lymphomas or up front in some aggressive lymphomas and in myeloma
  - Used as a rescue to allow high doses of chemotherapy
- Allogeneic: used in more in leukemia & later in relapsed lymphoma
  - Used as a rescue
  - Uses the Graft versus Leukemia/Lymphoma (GvL) effect
  - Bone Marrow vs Peripheral Blood vs Cord Blood
  - Various Donor options (related vs unrelated donors)
  - Myeloablative vs Reduced Intensity conditioning prior to stem cell infusion




**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Autologous Stem Cell Transplant: Procedure Overview








**SWEDISH**


CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Allogeneic Stem Cell Transplant Procedure Overview



# Graft vs Host Disease (GVHD)



# New Directions in Blood Cancer Treatment

## **Targeted Therapy:**

- blocks specific proteins in the cell growth and DNA replication pathway**

## **Immunotherapy**

- Antibodies & Antibody conjugates**
- Stimulating patient's immune system to fight cancer**
  - Checkpoint Inhibitors**
- Programming patient's immune system towards their blood cancer**
  - Chimeric Antigen Receptor T-Cells (CAR-T cells)**




**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Targeted Therapy






**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Immunotherapy- Antibodies



© 2008 RENEE CANNON

## Surface proteins targeted by immunotherapy

- > Naked monoclonal antibodies (mAbs)
- > Conjugated mAbs
  - Radioisotopes
  - Drugs
  - Toxins



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Rituximab (Rituxan)

**Monoclonal antibody against CD20**

**The first monoclonal antibody approved for use in cancer patients (1997)**

**Given once per week for 4 or 8 weeks or in combination with standard chemotherapy**






**SWEDISH**

CANCER INSTITUTE


Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

# Immunotherapy- Stimulating patient immune system



# Immunotherapy-

## Programming patient immune system to fight blood cancer



**CAR-T Cells-**  
Patient T-cells  
collected,  
genetically  
engineered to  
recognize your  
cancer better and  
kill it



# CAR-T Cells pending FDA Approval in ALL



Emily Whitehead, 12, and her parents, Tom and Kari Whitehead, appeared at an F.D.A. hearing on Tuesday about a treatment for leukemia that had saved Emily's life. Credit T.J. Kirkpatrick for The New York Times




**SWEDISH**

CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>

# Clinical Trials



<http://www.abta.org/about-us>

# Why Consider a Clinical Trial

**May offer additional or better options than standard therapy**

**Risks must be weighed against potential benefits**

## **Understanding clinical trials**

- > Animal studies
- > Phase I: tests dose and side effects
- > Phase II: tests effectiveness in a specific tumor
- > Phase III: compares standard therapy to new therapy
- > FDA Approval: commercially available

# Key Questions to Ask Your Doctor

**What type of blood cancer do I have? What is the specific subtype?**

**Is it indolent or aggressive?**

**What is the stage and genetics of my disease?**

**What are my treatment options?**

**What side effects may I experience and how can I deal with them?**

**Are there any clinical trials that I might benefit from, now or in the future?**





# SWEDISH

## CANCER INSTITUTE

Extraordinary **care.** Extraordinary **caring.**<sup>SM</sup>



LEUKEMIA &  
LYMPHOMA  
SOCIETY®

fighting blood cancers

**someday  
is today®**



Thank You



**SWEDISH**

CANCER INSTITUTE

Extraordinary **care**. Extraordinary **caring**.<sup>SM</sup>

